On January 4th, 2023, Sino Universal Pharma successfully obtained the GMP Certificate (Category B) issued by the Fujian Provincial Medical Products Administration. This marks a new milestone for SUP in the path of innovative services in the pharmaceutical industry chain and signifies a significant step towards becoming a technology-driven pharmaceutical service enterprise with international competitiveness.
In the future, SUP will continue to leverage its own strengths and actively promote the layout and construction of the MAH industry chain. We are committed to upholding the initial mission of "cherish Life and protect Health" driving pharmaceutical research and development innovation, enhancing our competitive edge, and contributing to the vigorous development of the Chinese pharmaceutical industry.
Simultaneously, the company will strictly adhere to regulatory requirements and actively fulfill the responsibilities of a drug marketing authorization holder. We will ensure the quality control and safety of marketed drugs, placing a strong emphasis on quality and safety standards.